Typical antipsychotics, like chlorpromazine, were developed in the 1950s with the aim to reduce the effects of dopamine to eliminate the positive symptoms of schizophrenia. however, they can also block other D2 receptor sites in the brain other than the mesolimbic pathway which can cause a problem with movement